CONGRATULATIONS FOR 2021 ACHIEVEMENTS!
Congratulations to Connor Hughes for his NRSA Fellowship!
Investigating the role of Eya3 in the regulation of innate immune signaling cascades in Triple Negative Breast Cancer
This grant centers around decoding the mechanism through which Eya3 is capable of regulating innate immune signaling cascades, particularly NF-kB, and how this regulation mediates tumor progression and metastasis. I am particularly interested in how tumor cell production of cytokines and chemokines facilitates immune evasion and enhances tumor cell aggressiveness in both tumor cell autonomous and non-autonomous ways.
Investigating the role of Eya3 in the regulation of innate immune signaling cascades in Triple Negative Breast Cancer
This grant centers around decoding the mechanism through which Eya3 is capable of regulating innate immune signaling cascades, particularly NF-kB, and how this regulation mediates tumor progression and metastasis. I am particularly interested in how tumor cell production of cytokines and chemokines facilitates immune evasion and enhances tumor cell aggressiveness in both tumor cell autonomous and non-autonomous ways.
CONGRATULATIONS FOR 2020 ACHIEVEMENTS!
Congratulations to Hengbo for his successful thesis defense. The virtual afterparty will be one to remember.
New publication!
Kong D, Hughes CJ, Ford HL. Cellular Plasticity in Breast Cancer Progression and Therapy. Front Mol Biosci. 2020 Apr 24;7:72. doi: 10.3389/fmolb.2020.00072. PMID: 32391382; PMCID: PMC7194153.
New Publication!
Zhou H, Blevins MA, Hsu JY, Kong D, Galbraith MD, Goodspeed A, Culp-Hill R, Oliphant MU, Ramirez D, Zhang L, Pineiro JT, Mathews Griner L, King R, Barnaeva E, Hu X, Southall NT, Ferrer M, Gustafson DL, Regan DP, D'Alessandro A, Costello JC, Patnaik S, Marugan J, Zhao R, Ford HL. A SIX1/EYA2 small molecule inhibitor disrupts EMT and metastasis. Cancer Res. 2020 Apr 27:canres.0435.2020. doi: 10.1158/0008-5472.CAN-20-0435. Epub ahead of print. PMID: 32341035.
Kong D, Hughes CJ, Ford HL. Cellular Plasticity in Breast Cancer Progression and Therapy. Front Mol Biosci. 2020 Apr 24;7:72. doi: 10.3389/fmolb.2020.00072. PMID: 32391382; PMCID: PMC7194153.
New Publication!
Zhou H, Blevins MA, Hsu JY, Kong D, Galbraith MD, Goodspeed A, Culp-Hill R, Oliphant MU, Ramirez D, Zhang L, Pineiro JT, Mathews Griner L, King R, Barnaeva E, Hu X, Southall NT, Ferrer M, Gustafson DL, Regan DP, D'Alessandro A, Costello JC, Patnaik S, Marugan J, Zhao R, Ford HL. A SIX1/EYA2 small molecule inhibitor disrupts EMT and metastasis. Cancer Res. 2020 Apr 27:canres.0435.2020. doi: 10.1158/0008-5472.CAN-20-0435. Epub ahead of print. PMID: 32341035.
New Publication!
Oliphant MUJ, Kong D, Zhou H, Lewis MT, Ford HL. Two Sides of the Same Coin: The Role of Developmental pathways and pluripotency factors in normal mammary stem cells and breast cancer metastasis. J Mammary Gland Biol Neoplasia. 2020 Apr 22. doi: 10.1007/s10911-020-09449-0. Epub ahead of print. PMID: 32323111.
New Publication!
Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, Campbell K, Cano A, Casanova J, Christofori G, Dedhar S, Derynck R, Ford HL, Fuxe J, García de Herreros A, Goodall GJ, Hadjantonakis AK, Huang RJY, Kalcheim C, Kalluri R, Kang Y, Khew-Goodall Y, Levine H, Liu J, Longmore GD, Mani SA, Massagué J, Mayor R, McClay D, Mostov KE, Newgreen DF, Nieto MA, Puisieux A, Runyan R, Savagner P, Stanger B, Stemmler MP, Takahashi Y, Takeichi M, Theveneau E, Thiery JP, Thompson EW, Weinberg RA, Williams ED, Xing J, Zhou BP, Sheng G; EMT International Association (TEMTIA). Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2020 Apr 16. doi: 10.1038/s41580-020-0237-9. Epub ahead of print. PMID: 32300252.
Oliphant MUJ, Kong D, Zhou H, Lewis MT, Ford HL. Two Sides of the Same Coin: The Role of Developmental pathways and pluripotency factors in normal mammary stem cells and breast cancer metastasis. J Mammary Gland Biol Neoplasia. 2020 Apr 22. doi: 10.1007/s10911-020-09449-0. Epub ahead of print. PMID: 32323111.
New Publication!
Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, Campbell K, Cano A, Casanova J, Christofori G, Dedhar S, Derynck R, Ford HL, Fuxe J, García de Herreros A, Goodall GJ, Hadjantonakis AK, Huang RJY, Kalcheim C, Kalluri R, Kang Y, Khew-Goodall Y, Levine H, Liu J, Longmore GD, Mani SA, Massagué J, Mayor R, McClay D, Mostov KE, Newgreen DF, Nieto MA, Puisieux A, Runyan R, Savagner P, Stanger B, Stemmler MP, Takahashi Y, Takeichi M, Theveneau E, Thiery JP, Thompson EW, Weinberg RA, Williams ED, Xing J, Zhou BP, Sheng G; EMT International Association (TEMTIA). Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2020 Apr 16. doi: 10.1038/s41580-020-0237-9. Epub ahead of print. PMID: 32300252.
CONGRATULATIONS FOR 2019 ACHIEVEMENTS!
CONGRATULATIONS FOR 2018 ACHIEVEMENTS!
Congratulations to Hengbo for an incredible 2018! Hengbo received an F99/K00 award in 2018, published 3 papers (including a co-first author in Nature Communications, a second author in J Clin Invest, and a first author review in Int J Biochem Cell Bio). In addition, Hengbo won the Department of Pharmacology Student Award for Outstanding Achievement AND The Cancer Biology Graduate Program Outstanding Research Award! Way to go Hengbo!
Mike has had another great year. His first author paper on the role of Six2 in mediating a cancer stem cell phenotype was just accepted in Cancer Research, he won numerous awards such as the 2018 Minority Scholar in Cancer Research Award to attend the 2018 AACR national meeting (where he gave a talk!), the 2018 Top Poster in Cancer Research Award at the New England Science Symposium at Harvard Medical School, and a poster award at the University of Colorado 33rd Annual Student Research Forum. He has just accepted a postdoctoral position at Harvard Medical School with Joan Brugge and Senthil Muthuswamy. Exciting times are ahead for Mike (after he defends his thesis!)....
Congratulations to Becky on her publication this year in J Clin Invest related to Eya3-mediated immune suppression in breast cancer. The paper was highlighted in Cancer Discovery shortly after its publication! Congratulations also for your new job as a scientist at The Gates Biomanufacturing Facility working on immune therapies. The Ford lab wishes you the best in your new position!
CONGRATULATIONS FOR 2017 ACHIEVEMENTS!
Sept. 2017-Congratulations to Mike for receiving a prestigious F99/K00 award from The National Cancer Institute! This award gives Mike 2 years of funding to finish his Dissertation work in our lab, and then 4 years of funding in a postdoctoral position!
2017- Nice shout-out to Mel from the ALSF regarding the postdoctoral fellowship grant she received in 2016 and the work she is doing on medulloblastoma!
Congratulations to Becky on her recent graduation (Dec. 2017)! Becky is moving on to a Scientist job at the Gates Biomanufacturing Center where she is working on CAR T-cell therapy. We wish her all the best!
Congrats to Hengbo on his recent publication in Nature Communications, as a co-first author along with Lingdi Zhang from the Zhao lab! Hengbo is shown here with his committee member, James DeGregori, after giving a talk at the King Symposium sponsored by the Department of Pathology and the Cancer Biology Graduate Program.
Congrats to Jessica for receiving a competitive Colorado Clinical Translational Sciences Initiative TSI predoctoral fellowship in 2017! As part of this fellowship, Jessica will continue to perform her work to understand the progression of rhabdomyosarcoma, using zebrafish, rodent, and human models, and will also gain some clinical insight into pediatric sarcomas through her shadowing of Tim Garrington at Children's Hospital, an Associate Professor in Pediatrics and Director of the Pedi-Heme Onc Fellowship Program.